Abbott completes its roughly $21B acquisition of Exact Sciences, maker of Cologuard

Abbott Laboratories

Abbott closed its purchase of Exact Sciences, which became a wholly owned subsidiary. The deal brings Cologuard, the Oncotype DX breast cancer test, the Oncodetect recurrence test and the Cancerguard blood test into Abbott, giving it a large position in US cancer screening and diagnostics.

• Exact Sciences holders received $105 per share in cash, about $21B in equity value.
• Exact Sciences shares last traded on Nasdaq on 20 March 2026.
• Products acquired: Cologuard, Oncotype DX, Oncodetect, Cancerguard.
• Abbott puts the US cancer screening and precision oncology diagnostics market at $60B.